乳脂摄入生物标志物与心血管疾病及全因死亡关联的队列研究与荟萃分析
该研究在瑞典4150名成人中测量血清十五烷酸(15:0),中位随访16.6年,发现15:0较高与心血管病风险降低相关。荟萃分析纳入18项观察性研究,显示15:0和十七烷酸(17:0)较高与心血管病风险降低相关,反式棕榈油酸(t16:1n-7)无显著关联,乳脂生物标志物与全因死亡无显著关联。
要点
- 血清15:0较高与心血管病风险呈线性剂量反应降低(HR 0.75/五分位间距)。
- 荟萃分析中15:0和17:0最高三分位与心血管病风险降低相关。
- t16:1n-7及乳脂生物标志物与全因死亡无显著关联。
核心结论
- 在18项观察性研究的荟萃分析中,15:0和17:0较高与心血管病风险降低相关。
- 乳脂生物标志物与全因死亡无显著关联,但各标志物研究数≤3项。
- 研究支持需开展临床和实验研究阐明因果性和生物学机制。
研究设计与样本
- 瑞典队列研究:4150名成人(51%女性,中位年龄60.5岁),基线测量血清胆固醇酯15:0,中位随访16.6年。
- 系统综述与荟萃分析纳入瑞典队列及17项队列、病例队列或巢式病例对照研究。
主要发现
- 瑞典队列中发生578例心血管病事件和676例死亡。
- 瑞典队列中15:0较高与心血管病风险线性剂量反应降低(HR 0.75/五分位间距;95%CI 0.61, 0.93;P=0.009)。
- 瑞典队列中15:0与全因死亡呈非线性关联(非线性P=0.03),死亡风险最低点约在15:0中位数附近。
- 荟萃分析中15:0和17:0最高三分位与总心血管病的相对风险分别为0.88(0.78, 0.99)和0.86(0.79, 0.93),t16:1n-7为1.01(0.91, 1.12)。
临床怎么用
- 血清15:0和17:0可作为乳脂摄入的客观生物标志物,与较低心血管病风险相关。
- 目前证据来自观察性研究,尚不能据此推荐通过增加乳脂摄入来预防心血管病。
局限性
- 生物标志物无法区分不同种类乳制品。
- 荟萃分析中多数研究(包括本队列)仅评估基线生物标志物,可能增加暴露水平错分风险。
- 乳脂生物标志物与全因死亡的荟萃分析中每个标志物研究数≤3项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to investigate the association of serum pentadecanoic acid (15:0), a biomarker of dairy fat intake, with incident cardiovascular disease (CVD) and all-cause mortality in a Swedish cohort study. We also systematically reviewed studies of the association of dairy fat biomarkers (circulating or adipose tissue levels of 15:0, heptadecanoic acid [17:0], and trans-palmitoleic acid [t16:1n-7]) with CVD outcomes or all-cause mortality. METHODS AND FINDINGS: We measured 15:0 in serum cholesterol esters at baseline in 4,150 Swedish adults (51% female, median age 60.5 years). During a median follow-up of 16.6 years, 578 incident CVD events and 676 deaths were identified using Swedish registers. In multivariable-adjusted models, higher 15:0 was associated with lower incident CVD risk in a linear dose-response manner (hazard ratio 0.75 per interquintile range; 95% confidence interval 0.61, 0.93, P = 0.009) and nonlinearly with all-cause mortality (P for nonlinearity = 0.03), with a nadir of mortality risk around median 15:0. In meta-analyses including our Swedish cohort and 17 cohort, case-cohort, or nested case-control studies, higher 15:0 and 17:0 but not t16:1n-7 were inversely associated with total CVD, with the relative risk of highest versus lowest tertile being 0.88 (0.78, 0.99), 0.86 (0.79, 0.93), and 1.01 (0.91, 1.12), respectively. Dairy fat biomarkers were not associated with all-cause mortality in meta-analyses, although there were ≤3 studies for each biomarker. Study limitations include the inability of the biomarkers to distinguish different types of dairy foods and that most studies in the meta-analyses (including our novel cohort study) only assessed biomarkers at baseline, which may increase the risk of misclassification of exposure levels. CONCLUSIONS: In a meta-analysis of 18 observational studies including our new cohort study, higher levels of 15:0 and 17:0 were associated with lower CVD risk. Our findings support the need for clinical and experimental studies to elucidate the causality of these relationships and relevant biological mechanisms.
引用
- Trieu K, Bhat S, Dai Z, et al. Biomarkers of dairy fat intake, incident cardiovascular disease, and all-cause mortality: A cohort study, systematic review, and meta-analysis. PLoS Med. 2021. PMID: 34547017. doi:10.1371/journal.pmed.1003763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。